FindTrial
Sign In

Spectrum of eye infections in COVID-19 affected individuals

Spectrum of posterior uveitis and endophthalmitis in patients with COVID-19.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/11/029346
Enrollment
20
Registered
2020-11-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 3: O- Medical and Surgical Health Condition 4: H438- Other disorders of vitreous body

Interventions

Intervention1: Pars plana vitrectomy with intraocular antibiotic injection: All patients with COVID-19 RT-PCR positive for their nasal swab and having inflammation in vitreous body/retina or uvea will

Sponsors

LV PRASAD EYE INSTITUTE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients with COVID-19 RT PCR positive for nasal swab, presenting with clinical features of posterior uveitis or endophthalmitis will be included in this study.

Exclusion criteria

Exclusion criteria: Those who are COVID RT-PCR negative in their nasal swab are excluded from the study. Those who are positive for rapid antigen test but negative for COVID RT-PCR in their nasal swab are also excluded from the study.

Design outcomes

Primary

MeasureTime frame
The primary outcome of this study will be type of organism found in the vitreous sampleTimepoint: To achieve the primary end point 2 weeks period will be required from the date of presentation.—

Secondary

MeasureTime frame
1. COVID RTC PCR RESULT OF VITREOUS BIOPSYTimepoint: 1 WEEK—

Countries

India

Contacts

Public ContactDrSameera Nayak

L.V Prasad eye institute

sameera@lvpei.org9390513748

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026